Bayer Intellectual Property Gmbh

Lead Discovery Center Gmbh

Merck Patent Gmbh

Max-Planck-Gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Qurient Co., Ltd.

Carsten Schultz-Fademrecht

Gerd Rühter

Philip Lienau

Gerhard Siemeister

Ulf Bömer

Rolf Bohlmann

Dirk Kosemund

Ulrich Lücking

Arne Scholz

Mark Jean Gnoth

Jan Eickhoff

Uwe Koch

Axel Ullrich

Oliver Schadt

Christina Esdar

Hana Kim

Jaeseung Kim

Gunther Zischinsky

Peter Nussbaumer

Kiyean Nam

Dongsik Park

SaeYeon Lee

Bert Klebl

Axel Choidas

Yeejin Jeon

Jeongjun Kim

Doohyung Lee

Seohyun Ahn

Jiye Ahn

Young-In Yang

Chun-won Jung

Alexander Wolf

Carsten Degenhart

Matthias Baumann

Chun-Won Jung

Yeong-In Yang

The present invention relates to novel compounds which are inhibitors of TAM (Axl, Mer and Tyro 3) and/or Met family receptor tyrosine kinases (RTKs). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by a receptor of the TAM family, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer, refractory cancer and cancer metastases.

Quinoline derivatives as TAM RTK inhibitors

The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).

4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group

The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia). 

The compound N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-5-ethyl-1 -(pyrimidin-5-yl)-1H-pyrazole-4-carboxamide and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios,is an inhibitor of RON and can be employed, for the treatment of cancer.

Quinoline inhibitor of the macrophage stimulating 1 receptor MSTR1

Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.

Pharmaceutically active pyrazolo-triazine derivatives

The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.

Pharmaceutically active compounds as Axl inhibitors

The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines

Growing community of inventors

Dortmund, Germany

Carsten Schultz-Fademrecht